open access

Vol 19, No 4 (2014)
Original research articles
Published online: 2014-07-01
Submitted: 2013-04-09
Get Citation

Toxicity outcome in patients treated with modulated arc radiotherapy for localized prostate cancer

Rafael E. Lengua, Maria F. Gonzalez, Kaory Barahona, Milton E. Ixquiac, Juan F. Lucero, Erick Montenegro, Jose L. Lopez Guerra, Javier Jaén, Luis A. Linares
DOI: 10.1016/j.rpor.2013.09.007
·
Rep Pract Oncol Radiother 2014;19(4):234-238.

open access

Vol 19, No 4 (2014)
Original research articles
Published online: 2014-07-01
Submitted: 2013-04-09

Abstract

Aim

This study evaluates the acute toxicity outcome in patients treated with RapidArc for localized prostate cancer.

Background

Modern technologies allow the delivery of high doses to the prostate while lowering the dose to the neighbouring organs at risk. Whether this dosimetric advantage translates into clinical benefit is not well known.

Materials and methods

Between December 2009 and May 2012, 45 patients with primary prostate adenocarcinoma were treated using RapidArc. All patients received 1.8[[ce:hsp sp="0.25"/]]Gy per fraction, the median dose to the prostate gland, seminal vesicles, pelvic lymph nodes and surgical bed was 80[[ce:hsp sp="0.25"/]]Gy (range, 77.4–81[[ce:hsp sp="0.25"/]]Gy), 50.4[[ce:hsp sp="0.25"/]]Gy, 50.4[[ce:hsp sp="0.25"/]]Gy and 77.4[[ce:hsp sp="0.25"/]]Gy (range, 75.6–79.2[[ce:hsp sp="0.25"/]]Gy), respectively.

Results

The time between the last session and the last treatment follow up was a median of 10 months (range, 3–24 months). The incidence of grade 3 acute gastrointestinal (GI) and genitourinary (GU) toxicity was 2.2% and 15.5%, respectively. Grade 2 acute GI and GU toxicity occurred in 30% and 27% of patients, respectively. No grade 4 acute GI and GU toxicity were observed. Older patients (>median) or patients with V60 higher than 35% had significantly higher rates of grade ≥2 acute GI toxicity compared with the younger ones.

Conclusions

RapidArc in the treatment of localized prostate cancer is tolerated well with no Grade >3 GI and GU toxicities. Older patients or patients with higher V60 had significantly higher rates of grade ≥2 acute GI toxicity. Further research is necessary to assess definitive late toxicity and tumour control outcome.

Abstract

Aim

This study evaluates the acute toxicity outcome in patients treated with RapidArc for localized prostate cancer.

Background

Modern technologies allow the delivery of high doses to the prostate while lowering the dose to the neighbouring organs at risk. Whether this dosimetric advantage translates into clinical benefit is not well known.

Materials and methods

Between December 2009 and May 2012, 45 patients with primary prostate adenocarcinoma were treated using RapidArc. All patients received 1.8[[ce:hsp sp="0.25"/]]Gy per fraction, the median dose to the prostate gland, seminal vesicles, pelvic lymph nodes and surgical bed was 80[[ce:hsp sp="0.25"/]]Gy (range, 77.4–81[[ce:hsp sp="0.25"/]]Gy), 50.4[[ce:hsp sp="0.25"/]]Gy, 50.4[[ce:hsp sp="0.25"/]]Gy and 77.4[[ce:hsp sp="0.25"/]]Gy (range, 75.6–79.2[[ce:hsp sp="0.25"/]]Gy), respectively.

Results

The time between the last session and the last treatment follow up was a median of 10 months (range, 3–24 months). The incidence of grade 3 acute gastrointestinal (GI) and genitourinary (GU) toxicity was 2.2% and 15.5%, respectively. Grade 2 acute GI and GU toxicity occurred in 30% and 27% of patients, respectively. No grade 4 acute GI and GU toxicity were observed. Older patients (>median) or patients with V60 higher than 35% had significantly higher rates of grade ≥2 acute GI toxicity compared with the younger ones.

Conclusions

RapidArc in the treatment of localized prostate cancer is tolerated well with no Grade >3 GI and GU toxicities. Older patients or patients with higher V60 had significantly higher rates of grade ≥2 acute GI toxicity. Further research is necessary to assess definitive late toxicity and tumour control outcome.

Get Citation

Keywords

Prostate cancer; RapidArc; Toxicity; Arc therapy

About this article
Title

Toxicity outcome in patients treated with modulated arc radiotherapy for localized prostate cancer

Journal

Reports of Practical Oncology and Radiotherapy

Issue

Vol 19, No 4 (2014)

Pages

234-238

Published online

2014-07-01

DOI

10.1016/j.rpor.2013.09.007

Bibliographic record

Rep Pract Oncol Radiother 2014;19(4):234-238.

Keywords

Prostate cancer
RapidArc
Toxicity
Arc therapy

Authors

Rafael E. Lengua
Maria F. Gonzalez
Kaory Barahona
Milton E. Ixquiac
Juan F. Lucero
Erick Montenegro
Jose L. Lopez Guerra
Javier Jaén
Luis A. Linares

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: journals@viamedica.pl